Latest Administration News

Nufarm Limited reported a 3% revenue increase to $1.81 billion for the half-year ended March 2025, driven by Crop Protection volume growth. However, net profit after tax fell 39% amid fish oil pricing pressures and higher operating costs, prompting the board to withhold an interim dividend.

Webjet Group Limited reported a stable FY25 EBITDA of $39.4 million despite a 7% decline in bookings driven by soft domestic flight demand. Growth in international bookings and strategic investments underpin a confident outlook.

Webjet Group posted a solid FY25 financial performance with underlying EBITDA up 1% despite a 7% drop in bookings, supported by growth in international travel and disciplined cost management. The company maintains a strong cash position and sets FY26 guidance in line with current results.

Webjet Group Limited reports resilient FY25 results following its recent demerger, with a strategic plan to double transaction value by FY30. Despite macroeconomic headwinds, the company maintains strong cash reserves and outlines ambitious growth initiatives.

Yowie Group Ltd has firmly rejected the validity of director removal and nomination notices purportedly from Keybridge Capital, while confirming its status as Keybridge’s largest creditor with over $6.6 million owed. The company also detailed a recent share placement amid ongoing regulatory scrutiny.

HomeCo Daily Needs REIT has announced a quarterly distribution of 2.125 cents per unit for the period ending March 31, 2025, reaffirming its commitment to delivering steady income to investors.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

State Street Global Advisors announces key updates to its SPDR Fixed Income ETFs, including a significant fee reduction for the Australian Bond ETF and a rebranding to incorporate the iBoxx index name, effective June 2025.